Lamifiban (TFA)

• UNSPSC Description:

  Lamifiban TFA is a nonpeptide glycoprotein IIb/IIIa receptor and platelet aggregation antagonist. Lamifiban TFA in combination with thrombolytic therapy effectively restores coronary arterial patency. Lamifiban TFA is promising for research of acute coronary syndromes[1].

• Target Antigen:

  Others

• Type:

  Reference compound

• Related Pathways:

  Others

• Field of Research:

  Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/lamifiban-tfa.html

• Smiles:

  OC(C(F)(F)F)=O.O=C(N1CCC(CC1)OCC(O)=O)[C@@H](NC(C2=CC=C(C=C2)C(N)=N)=O)CC3=CC=C(C=C3)O

• Molecular Weight:

  582.53

• References & Citations:

  [1]Moliterno DJ, et al. Randomized, Placebo-Controlled Study of Lamifiban with Thrombolytic Therapy for the Treatment of Acute Myocardial Infarction: Rationale and Design for the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) Study. J Thromb Thrombolysis. 1995;2(3):165-169.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  144412-50-0